First Patient Enrolled in the STRIDE-1 Study Second Product Candidate Axsome Has Advanced into a Pivotal Trial NEW YORK, March 17, 2016 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company ... 4 Traders, 1 month ago
(Before It's News)An Exclusive You Have To See: Facebook's Diabolical New Initiative Is Causing Mass Exodus—1000s Shut Down As They Discover… by Arjun Walia, Collective Evolution It's hard to believe that approximately one in every two people ...Before It's News, 1 month ago
Full Show: Preventing Myeloma Before it Gets Started with Dr. Irene Ghobrial, MD, Dana Farber Cancer Institue
Dr. Irene Ghobrial, MD Dana Farber Cancer Institute / Harvard School of Medicine Interview Date: March 17, 2016 Summary Can we prevent smoldering myeloma or MGUS from progressing to active myeloma? Dr. Irene Ghobrial, MD wonders why we are ...Myeloma Crowd, 1 month ago Full Show: Achieving Minimal Residual Disease with Myeloma Vaccines with Dr. David Avigan, MD Beth Israel Deaconess Medical Center Myeloma Crowd, 1 month ago
Researchers from Hong Kong and the U.S. have developed a new statistical and mapping method that could help identify drug targets for treating leukaemia. In chronic myelogenous leukaemia (CML), too many stem cells in the bone marrow are ...Innovations Report, 2 days ago
When it comes to protecting your body's 206 bones, it's never too early to start, says Abby Abelson, MD, chair of the department of rheumatic and immunologic diseases at the Cleveland Clinic. "Many women don't even think about their bones until they ...ABC News, 4 days ago
Aduro Biotech Reports Publishing of Key Preclinical Data Highlighting New Approach to Treat Multiple Myeloma
Aduro Biotech, Inc. (Nasdaq: ADRO ) today announced the publication of a pivotal paper elucidating the roles of B cell maturation antigen (BCMA) and its ligand A PRoliferation-Inducing Ligand (APRIL) in multiple myeloma, highlighting the potential ...Morningstar.com, 6 days ago Aduro Biotech Announces Key Preclinical Data Published Highlighting New Approach to Treat Multiple Myeloma 4 Traders, 6 days ago
AbbVie Receives FDA Accelerated Approval of Venclexta venetoclax Tablets, the First BCL-2 Inhibitor in Relapsed/Refractory Chronic Lymphocytic...
AbbVie Receives FDA Accelerated Approval of Venclexta venetoclax Tablets, the First BCL-2 Inhibitor in Relapsed/Refractory Chronic Lymphocytic Leukemia Patients with 17p Deletion By a News Reporter-Staff News Editor at Politics & Government ...Pharmacy Choice, 6 days ago 4/28/16 - AbbVie Receives FDA Accelerated Approval of Venclexta venetoclax Tablets, the First BCL-2 Inhibitor in Relapsed/Refractory Chronic Lymphocytic... Pharmacy Choice, 6 days ago 4/12/16 - AbbVie Receives FDA Accelerated Approval of Venclexta?¢ (venetoclax) Tablets, the First BCL-2 Inhibitor in Relapsed/Refractory Chronic Lymphocytic Leukemia Patients with 17p Deletion Pharmacy Choice, 3 weeks ago 4/11/16 - AbbVie Receives FDA Accelerated Approval of Venclexta?¢ (venetoclax) Tablets, the First BCL-2 Inhibitor in Relapsed/Refractory Chronic Lymphocytic Leukemia Patients with 17p Deletion Pharmacy Choice, 3 weeks ago
1 , Jeremy V. Edwards 2 , C. Lorrie Epling 3 , Elizabeth Sinclair 3 , Douglas S. Hawkins 4 , Holcombe E. Grier 5 , Katherine A. Janeway 5 , Phillip Barnette 6 , Elizabeth McIlvaine 7 , Mark D. Krailo 7 , Donald A. Barkauskas 7 , Katherine ...Clinical Cancer Research, 1 week ago
EurekAlert! provides embargoed and breaking science news you can't afford to miss. EurekAlert! offers a one-stop science news distribution service you can trust. EurekAlert! is a service of the American Association for the Advancement of Science. ...EurekAlert!, 2 weeks ago Ten Researchers to Receive Heinz Maier-Leibnitz Prizes Alpha Galileo, 4 weeks ago
Bioquark Inc. and Revita Life Sciences Receive IRB Approval for First-In-Human Brain Death Study April 20, 2016The Reanima Project - Is Death Reversible?
With the convergence of the disciplines of regenerative biology, cognitive neuroscience, and clinical resuscitation, we are poised to delve into an area of scientific understanding previously inaccessible with existing technologies. - Ira S. Pastor, ...PRWeb, 2 weeks ago
More from: , Minyanville...and 5 other sources
on your WebpageAdd Widget >Get your members hooked!